 Regeneron Pharmaceuticals Inc and Sanofi SA said they would begin a latestage study of an experimental treatment for chronic eczema in hopes of gaining US regulatory approval following midstage studies in which the drug significantly reduced patients skin rashes and itchiness  The drug called dupilumab is thought to treat the disease by blocking the bodys allergic response to environmental antigens Moderate to severe eczema also known as atopic dermatitis affects as many as one million people in the US according
  